204 related articles for article (PubMed ID: 37499338)
1. Defining progression independent of relapse activity (PIRA) in adult patients with relapsing multiple sclerosis: A systematic review
Sharrad D; Chugh P; Slee M; Bacchi S
Mult Scler Relat Disord; 2023 Oct; 78():104899. PubMed ID: 37499338
[TBL] [Abstract][Full Text] [Related]
2. Harmonizing Definitions for Progression Independent of Relapse Activity in Multiple Sclerosis: A Systematic Review.
Müller J; Cagol A; Lorscheider J; Tsagkas C; Benkert P; Yaldizli Ö; Kuhle J; Derfuss T; Sormani MP; Thompson A; Granziera C; Kappos L
JAMA Neurol; 2023 Nov; 80(11):1232-1245. PubMed ID: 37782515
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Multiple Sclerosis Progression and Relapse Activity in Children.
Iaffaldano P; Portaccio E; Lucisano G; Simone M; Manni A; Guerra T; Paolicelli D; Betti M; De Meo E; Pastò L; Razzolini L; Rocca MA; Ferrè L; Brescia Morra V; Patti F; Zaffaroni M; Gasperini C; De Luca G; Ferraro D; Granella F; Pozzilli C; Romano S; Gallo P; Bergamaschi R; Coniglio MG; Lus G; Vianello M; Banfi P; Lugaresi A; Totaro R; Spitaleri D; Cocco E; Di Palma F; Maimone D; Valentino P; Torri Clerici V; Protti A; Maniscalco GT; Salemi G; Pesci I; Aguglia U; Lepore V; Filippi M; Trojano M; Amato MP;
JAMA Neurol; 2024 Jan; 81(1):50-58. PubMed ID: 38010712
[TBL] [Abstract][Full Text] [Related]
5. Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials.
Kappos L; Wolinsky JS; Giovannoni G; Arnold DL; Wang Q; Bernasconi C; Model F; Koendgen H; Manfrini M; Belachew S; Hauser SL
JAMA Neurol; 2020 Sep; 77(9):1132-1140. PubMed ID: 32511687
[TBL] [Abstract][Full Text] [Related]
6. Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression.
Portaccio E; Betti M; De Meo E; Addazio I; Pastò L; Razzolini L; Totaro R; Spitaleri D; Lugaresi A; Cocco E; Onofrj M; Di Palma F; Patti F; Maimone D; Valentino P; Torri Clerici V; Protti A; Ferraro D; Lus G; Maniscalco GT; Brescia Morra V; Salemi G; Granella F; Pesci I; Bergamaschi R; Aguglia U; Vianello M; Simone M; Lepore V; Iaffaldano P; Comi G; Filippi M; Trojano M; Amato MP;
J Neurol; 2024 May; ():. PubMed ID: 38805052
[TBL] [Abstract][Full Text] [Related]
7. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
[TBL] [Abstract][Full Text] [Related]
8. How patients with multiple sclerosis acquire disability.
Lublin FD; Häring DA; Ganjgahi H; Ocampo A; Hatami F; Čuklina J; Aarden P; Dahlke F; Arnold DL; Wiendl H; Chitnis T; Nichols TE; Kieseier BC; Bermel RA
Brain; 2022 Sep; 145(9):3147-3161. PubMed ID: 35104840
[TBL] [Abstract][Full Text] [Related]
9. Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis.
Cagol A; Schaedelin S; Barakovic M; Benkert P; Todea RA; Rahmanzadeh R; Galbusera R; Lu PJ; Weigel M; Melie-Garcia L; Ruberte E; Siebenborn N; Battaglini M; Radue EW; Yaldizli Ö; Oechtering J; Sinnecker T; Lorscheider J; Fischer-Barnicol B; Müller S; Achtnichts L; Vehoff J; Disanto G; Findling O; Chan A; Salmen A; Pot C; Bridel C; Zecca C; Derfuss T; Lieb JM; Remonda L; Wagner F; Vargas MI; Du Pasquier R; Lalive PH; Pravatà E; Weber J; Cattin PC; Gobbi C; Leppert D; Kappos L; Kuhle J; Granziera C
JAMA Neurol; 2022 Jul; 79(7):682-692. PubMed ID: 35575778
[TBL] [Abstract][Full Text] [Related]
10. Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis.
Tur C; Carbonell-Mirabent P; Cobo-Calvo Á; Otero-Romero S; Arrambide G; Midaglia L; Castilló J; Vidal-Jordana Á; Rodríguez-Acevedo B; Zabalza A; Galán I; Nos C; Salerno A; Auger C; Pareto D; Comabella M; Río J; Sastre-Garriga J; Rovira À; Tintoré M; Montalban X
JAMA Neurol; 2023 Feb; 80(2):151-160. PubMed ID: 36534392
[TBL] [Abstract][Full Text] [Related]
11. Teriflunomide for multiple sclerosis.
He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
[TBL] [Abstract][Full Text] [Related]
12. Active and non-active progression independent of relapse activity within the first 20 years of relapsing multiple sclerosis.
Maarouf A; Stellmann JP; Rico A; Boutiere C; Demortiere S; Durozard P; Zaaraoui W; Ranjeva JP; Pelletier J; Audoin B
J Neurol Neurosurg Psychiatry; 2024 May; ():. PubMed ID: 38719433
[TBL] [Abstract][Full Text] [Related]
13. Alemtuzumab for multiple sclerosis.
Riera R; Porfírio GJ; Torloni MR
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD011203. PubMed ID: 27082500
[TBL] [Abstract][Full Text] [Related]
14. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
15. Intrathecal kappa free light chain synthesis is associated with worse prognosis in relapsing-remitting multiple sclerosis.
Rosenstein I; Axelsson M; Novakova L; Malmeström C; Blennow K; Zetterberg H; Lycke J
J Neurol; 2023 Oct; 270(10):4800-4811. PubMed ID: 37314506
[TBL] [Abstract][Full Text] [Related]
16. Progression Independent of Relapse Activity in Multiple Sclerosis: Closer to Solving the Pathologic Puzzle.
Tur C; Rocca MA
Neurology; 2024 Jan; 102(1):e207936. PubMed ID: 38165383
[TBL] [Abstract][Full Text] [Related]
17. Bias due to selective inclusion and reporting of outcomes and analyses in systematic reviews of randomised trials of healthcare interventions.
Page MJ; McKenzie JE; Kirkham J; Dwan K; Kramer S; Green S; Forbes A
Cochrane Database Syst Rev; 2014 Oct; 2014(10):MR000035. PubMed ID: 25271098
[TBL] [Abstract][Full Text] [Related]
18. Association of serum glial fibrillary acidic protein with progression independent of relapse activity in multiple sclerosis.
Rosenstein I; Nordin A; Sabir H; Malmeström C; Blennow K; Axelsson M; Novakova L
J Neurol; 2024 Apr; ():. PubMed ID: 38668889
[TBL] [Abstract][Full Text] [Related]
19. Multiple sclerosis: role of meningeal lymphoid aggregates in progression independent of relapse activity.
Ransohoff RM
Trends Immunol; 2023 Apr; 44(4):266-275. PubMed ID: 36868982
[TBL] [Abstract][Full Text] [Related]
20. Contribution of relapse-associated worsening to overall disability accrual in patients with relapsing-onset multiple sclerosis: A mediation analysis.
Chen B; Ji SQ; Shen F; Tian DS; Bu BT
Mult Scler Relat Disord; 2022 Mar; 59():103555. PubMed ID: 35093839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
